title: Gene therapeutic approach to primary and metastatic brain tumors: I. CD44 variant pre-RNA alternative splicing as a CEPT control element.
abstract: Our laboratory and others have shown alternative splicing of up to ten exons at a discrete extracellular site to be primarily responsible for the generation of CD44 variant (CD44v) isoforms. Based on clear differences in the expression of these CD44v isoforms between normal and malignant tissues, we believe that elucidation of the mechanisms underlying the regulation of CD44 alternative splicing may provide a new gene therapeutic targeting approach based on CD44 pre-mRNA processing in vivo. This strategy incorporates utilization of CD44 alternative splicing control elements into a chimeric enzyme/prodrug therapy (CEPT), a novel modification of the virus-directed enzyme/prodrug therapy (VDEPT) approach for the treatment of brain metastases from tumors of systemic origin. As initial steps towards the development of a gene therapeutic approach based on targeting tumor cell expression of specific CD44v alternatively spliced isoforms, we have: (1) developed a novel in vivo assay system that allows the rapid analyses of potentially therapeutic CD44 alternative splicing minigene constructs; and (2) cloned the E. coli cytosine deaminase (CD) gene and fused its enzymatically active domain to alternatively spliced CD44 exons (CD44/CD). Deamination of cytosine by this CD44/CD chimeric fusion protein is demonstrated in E. coli cell lysates to be equal to that of wild type cytosine deaminase.
authors: Department of Pathology, University of Pittsburgh, Pennsylvania, USA.
authors: D C
authors: DC
authors: Asman
authors: J F
authors: JF
authors: Dirks
authors: L
authors: L
authors: Ge
authors: N M
authors: NM
authors: Resnick
authors: L A
authors: LA
authors: Salvucci
authors: J T
authors: JT
authors: Gau
authors: M J
authors: MJ
authors: Becich
authors: D L
authors: DL
authors: Cooper
authors: G J
authors: GJ
authors: Dougherty
mesh_terms: D017398:Alternative Splicing; D000818:Animals; D001483:Base Sequence; D001921:Brain / Q000378:metabolism; D001932:Brain Neoplasms / Q000556:secondary* / Q000628:therapy*; D043525:Cytosine Deaminase; D017931:DNA Primers; D004926:Escherichia coli / Q000201:enzymology / Q000235:genetics; D005091:Exons; D005798:Genes, Bacterial; D015316:Genetic Therapy; D014644:Genetic Variation; D006801:Humans; D018960:Hyaluronan Receptors / Q000096:biosynthesis* / Q000235:genetics; D007438:Introns; D008969:Molecular Sequence Data; D009700:Nucleoside Deaminases / Q000096:biosynthesis* / Q000235:genetics; D016133:Polymerase Chain Reaction; D012322:RNA Precursors / Q000378:metabolism*; D012333:RNA, Messenger / Q000096:biosynthesis*; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis; D015183:Restriction Mapping
chemical_list: D017931:DNA Primers; D018960:Hyaluronan Receptors; D012322:RNA Precursors; D012333:RNA, Messenger; D011993:Recombinant Fusion Proteins; D009700:Nucleoside Deaminases; D043525:Cytosine Deaminase